BELLUS Health Cough, Inc.

Primary Objectives: To evaluate the effect of BLU-5937 on 24-hour cough frequency at Week 24 compared to placebo in adult patients with RCC (including chronic cough of unknown etiology) with a baseline 24-hour cough frequency ≥8 coughs/hour and to determine the safety of BLU-5937 compared to placebo in adult patients with RCC (including chronic cough of unknown etiology) as of Week 24 Secondary Objectives: To evaluate the effect of BLU-5937 on other measures, including cough frequency and PROs Exploratory Objectives: To evaluate the effect of BLU-5937 on other measures, including cough frequency and PROs